Keith Gottesdiener

TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.

TL;DR: Circulating Acrp30 levels were suppressed 5-fold in patients with severe insulin resistance in association with PPARγ agonists, and in a cohort of normal human subjects, 14-d treatment with rosiglitazone also produced a 130% increase in circulating Acr p30 levels vs. placebo.

TL;DR: In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.

TL;DR: Sitagliptin is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP‐IV) currently in phase III development for the treatment of type 2 diabetes.

TL;DR: Patients with rare defects in the gene encoding proopiomelanocortin have extreme early-onset obesity, hyperphagia, hypopigmentation, and hypocortisolism and are treated with setmelanotide, a new melanocortIn-4 receptor agonist, which had a sustainable reduction in hunger and substantial weight loss.